Evidence map›Paper›PMID 39037224›Full record

ArticleMicrobiology spectrum2024

Advancing COVID-19 diagnostics: rapid detection of intact SARS-CoV-2 using viability RT-PCR assay.

Judith M J Veugen, Tom Schoenmakers, Inge H M van Loo, Bart L Haagmans, Mathie P G Leers, Mart M Lamers, Mayk Lucchesi, Bas C T van Bussel, Walther N K A van Mook, Rudy M M A Nuijts and 3 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Identifying viableMicrobiology spectrum · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Evaluation of Torquetenovirus (TTV) Particle Integrity Utilizing PMAxx™.International journal of molecular sciences · 2025
    Article
  7. Article
  8. EnhancingMicrobiology spectrum · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Judith M J VeugenUniversity Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands.ORCID 0000-0002-0469-5781
Tom SchoenmakersDepartment of Clinical Chemistry and Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.
Inge H M van LooDepartment of Medical Microbiology, Infectious Diseases & Infection Prevention, Maastricht University Medical Center, Maastricht, the Netherlands.
Bart L HaagmansViroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6221-2015
Mathie P G LeersDepartment of Clinical Chemistry and Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, the Netherlands.
Mart M LamersViroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-1431-4022
Mayk LucchesiDepartment of Medical Microbiology, Infectious Diseases & Infection Prevention, Maastricht University Medical Center, Maastricht, the Netherlands.
Bas C T van BusselCare and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.
Walther N K A van MookDepartment of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.
Rudy M M A NuijtsUniversity Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands.
Paul H M SavelkoulDepartment of Medical Microbiology, Infectious Diseases & Infection Prevention, Maastricht University Medical Center, Maastricht, the Netherlands.
Mor M DickmanUniversity Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands.
Petra F G WolffsDepartment of Medical Microbiology, Infectious Diseases & Infection Prevention, Maastricht University Medical Center, Maastricht, the Netherlands.ORCID 0000-0002-5326-3985

Funding

ZonMw (Netherlands Organisation for Health Research and Development) 10430102110002
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Commonly used methods for both clinical diagnosis of SARS-CoV-2 infection and management of infected patients involve the detection of viral RNA, but the presence of infectious virus particles is unknown. Viability PCR (v-PCR) uses a photoreactive dye to bind non-infectious RNA, ideally resulting in the detection of RNA only from intact virions. This study aimed to develop and validate a rapid v-PCR assay for distinguishing intact and compromised SARS-CoV-2. Propidium monoazide (PMAxx) was used as a photoreactive dye. Mixtures with decreasing percentages of intact SARS-CoV-2 (from 100% to 0%) were prepared from SARS-CoV-2 virus stock and a clinical sample. Each sample was divided into a PMAxx-treated part and a non-PMAxx-treated part. Reverse transcription-PCR (RT-PCR) using an in-house developed SARS-CoV-2 viability assay was then applied to both sample sets. The difference in intact SARS-CoV-2 was determined by subtracting the cycle threshold ( IMPORTANCE: This study developed a novel method that can help determine whether someone who has been diagnosed with coronavirus disease 2019 (COVID-19) is still capable of spreading the virus to others. Current tests only detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, but cannot tell whether the particles are still intact and can thus infect cells. The researchers used a dye that selectively blocks the detection of damaged virions and free RNA. They showed that this viability PCR reliably distinguishes intact SARS-CoV-2 capable of infecting from damaged SARS-CoV-2 or free RNA in both cultured virus samples and a clinical sample. Being able to quickly assess contagiousness has important implications for contact tracing and safely ending isolation precautions. This viability PCR technique provides a simple way to obtain valuable information, beyond just positive or negative test results, about the actual risk someone poses of transmitting SARS-CoV-2 through the air or surfaces they come into contact with.

Indexed as

COVID-19Reverse Transcriptase Polymerase Chain ReactionRNA, ViralSARS-CoV-2AzidesCOVID-19 Nucleic Acid TestingCOVID-19 TestingHumansPropidiumSensitivity and SpecificityAzidesPropidiumpropidium monoazideRNA, Viralinfectiousnessintact virus particlesPMAxxSARS-CoV-2viability PCRviral shedding

Identifiers

PMID39037224
PMCPMC11370235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.